PABLO MARIA ALBERTO POMERANTZEFF
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/65, Hospital das Clínicas, Faculdade de Medicina
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/65, Hospital das Clínicas, Faculdade de Medicina
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
- Is Heart Team Fundamental to Aortic Stenosis Transcatheter Treatment?(2014) ROSA, Vitor Emer Egypto; LOPES, Antnio Sergio de Santis Andrade; ACCORSI, Tarso Augusto Duenhas; LEMOS NETO, Pedro Alves; POMERANTZEFF, Pablo Maria Alberto; TARASOUTCHI, Flavio
- Patient Management with Metallic Valve Prosthesis during Pregnancy and Postpartum Period(2015) GARCEZ, Juliane Dantas Seabra; ROSA, Vitor Emer Egypto; LOPES, Antonio Sergio de Santis Andrade; ACCORSI, Tarso Augusto Duenhas; FERNANDES, Joao Ricardo Cordeiro; POMERANTZEFF, Pablo Maria; AVILA, Walkiria Samuel; TARASOUTCHI, FlavioProsthetic thrombosis is a rare complication, but it has high mortality and morbidity. Young women of childbearing age that have prosthetic heart valves are at increased risk of thrombosis during pregnancy due to changes in coagulation factors. Anticoagulation with adequate control and frequent follow-up if pregnancy occurs must be performed in order to prevent complications related to anticoagulant use. Surgery remains the treatment of choice for prosthetic heart valve thrombosis in most clinical conditions. Patients with metallic prosthetic valves have an estimated 5% risk of thrombosis during pregnancy and maternal mortality of 1.5% related to the event. Anticoagulation with vitamin K antagonists during pregnancy is related to varying degrees of complications at each stage of the pregnancy and postpartum periods. Warfarin sodium crosses the placental barrier and when used in the first trimester of pregnancy is a teratogenic agent, causing 1-3% of malformations characterized by fetal warfarin syndrome and also constitutes a major cause of miscarriage in 10-30% of cases. In the third trimester and at delivery, the use of warfarin is associated with maternal and neonatal bleeding in approximately 5 to 15% of cases, respectively. On the other hand, inadequate anticoagulation, including the suspension of the oral anticoagulants aiming at fetal protection, carries a maternal risk of about 25% of metallic prosthesis thrombosis, particularly in the mitral valve. This fact is also due to the state of maternal hypercoagulability with activation of coagulation factors V, VI, VII, IX, X, platelet activity and fibrinogen synthesis, and decrease in protein S levels. The Registry of Pregnancy and Cardiac Disease (ROPAC), assessing 212 pregnant women with metal prosthesis, showed that prosthesis thrombosis occurred in 10 (4.7%) patients and maternal hemorrhage in 23.1%, concluding that only 58% of patients with metallic prosthesis had a complication-free pregnancy(1-7).
article Brazilian Cardiology Society Statement for Management of Pregnancy and Family Planning in Women with Heart Disease - 2020 (vol 14, pg 849, 2020)(2020) AVILA, Walkiria Samuel; ALEXANDRE, Elizabeth Regina Giunco; CASTRO, Marildes Luiza de; LUCENA, Alexandre Jorge Gomes de; MARQUES-SANTOS, Celi; FREIRE, Claudia Maria Vilas; ROSSI, Eduardo Giusti; CAMPANHARO, Felipe Favorette; RIVERA, Ivan Romero; COSTA, Maria Elizabeth Navegantes Caetano; RIVERA, Maria Alayde Mendonca; CARVALHO, Regina Coeli Marques de; ABZAID, Alexandre; MORON, Antonio Fernandes; RAMOS, Auristela Isabel de Oliveira; ALBUQUERQUE, Carlos Japhet da Mata; FEIO, Claudine Maia Alves; BORN, Daniel; SILVA, Fabio Bruno da; NANI, Fernando Souza; TARASOUTCHI, Flavio; COSTA JUNIOR, Jose de Ribamar; MELO FILHO, Jose Xavier de; KATZ, Leila; ALMEIDA, Maria Cristina Costa; GRINBERG, Max; AMORIM, Melania Maria Ramos de; MELO, Nilson Roberto de; MEDEIROS, Orlando Otavio de; POMERANTZEFF, Pablo Maria Alberto; BRAGA, Sergio Luiz Navarro; CRISTINO, Sonia Conde; MARTINEZ, Tania Leme da Rocha; LEAL, Tatiana de Carvalho Andreuci Torres- Update of the Brazilian Guidelines for Valvular Heart Disease-2020(2020) TARASOUTCHI, Flavio; MONTERA, Marcelo Westerlund; RAMOS, Auristela Isabel de Oliveira; SAMPAIO, Roney Orismar; ROSA, Vitor Emer Egypto; ACCORSI, Tarso Augusto Duenhas; SANTIS, Antonio de; FERNANDES, Joao Ricardo Cordeiro; PIRES, Lucas Jose Tachotti; SPINA, Guilherme S.; VIEIRA, Marcelo Luiz Campos; LAVITOLA, Paulo de Lara; AVILA, Walkiria Samuel; PAIXAO, Milena Ribeiro; BIGNOTO, Tiago; TOGNA, Dorival Julio Della; MESQUITA, Evandro Tinoco; ESTEVES, William Antonio de Magalhaes; ATIK, Fernando; COLAFRANCESCHI, Alexandre Siciliano; MOISES, Valdir Ambrosio; KIYOSE, Alberto Takeshi; POMERANTZEFF, Pablo M. A.; LEMOS, Pedro A.; BRITO JUNIOR, Fabio Sandoli de; WEKSLER, Clara; BRANDAO, Carlos Manuel de Almeida; POFFO, Robinson; SIMOES, Ricardo; RASSI, Salvador; LEAES, Paulo Ernesto; MOURILHE-ROCHA, Ricardo; PENA, Jose Luiz Barros; JATENE, Fabio Biscegli; BARBOSA, Marcia de Melo; ABIZAID, Alexandre; RIBEIRO, Henrique Barbosa; BACAL, Fernando; ROCHITTE, Carlos Eduardo; FONSECA, Jose Honorio de Almeida Palma; GHORAYEB, Samira Kaissar Nasr; LOPES, Marcelo Antonio Cartaxo Queiroga; SPINA, Salvador Vicente; PIGNATELLI, Ricardo H.; SARAIVA, Jose Francisco Kerr
- Update of the Brazilian Guidelines for Valvular Heart Disease: An Approach to Anatomically Important Lesions Introduction(2017) TARASOUTCHI, Flavio; MONTERA, Marcelo Westerlund; RAMOS, Auristela Isabel de Oliveira; SAMPAIO, Roney Orismar; ROSA, Vitor Emer Egypto; DUENHASACCORSI, Tarso Augusto; LOPES, Antonio Sergio de Santis Andrade; FERNANDES, Joao Ricardo Cordeiro; PIRES, Lucas Jose Tachotti; SPINA, Guilherme Sobreira; VIEIRA, Marcelo Luiz Campos; LAVITOLA, Paulo de Lara; BIGNOTO, Tiago Costa; TOGNA, Dorival Julio Della; MESQUITA, Evandro Tinoco; ESTEVES, William Antonio de Magalhaes; ATIK, Fernando Antibas; COLAFRANCESCHI, Alexandre Siciliano; MOISES, Valdir Ambrosio; KIYOSE, Alberto Takeshi; POMERANTZEFF, Pablo Maria Alberto; LEMOS NETO, Pedro Alves; BRITO JUNIOR, Fabio Sandoli de; WEKSLER, Clara; BRANDAO, Carlos Manuel de Almeida; POFFO, Robinson; SIMOES, Ricardo; RASSI, Salvador; LEAES, Paulo Ernesto; ROCHA, Ricardo Mourilhe; PENA, Jose Luiz Barros; JATENE, Fabio Biscegli; BARBOSA, Marcia de Melo; SOUZA NETO, Joao David de; SARAIVA, Jose Francisco Kerr
- Mitral Valve Repair in Young Rheumatic Patients(2019) POMERANTZEFF, Pablo Maria Alberto
- InsCor: um método simples e acurado para avaliação do risco em cirurgia cardíaca(2013) MEJA, Omar A. V.; LISBOA, Luiz A. F.; PUIG, Luiz B.; MOREIRA, Luiz Felipe P.; DALLAN, Luis A. O.; POMERANTZEFF, Pablo M. A.; JATENE, Fabio B.; STOLF, Noedir A. G.Background: Risk scores show difficulties to attain the same performance in different populations. Objective: To create a simple and accurate risk assessment model for patients submitted to surgery due to coronary and/or valvular disease at Instituto do Coracao da Universidade de Sao Paulo (InCor-HCFMUSP). Methods: Between 2007 and 2009, 3,000 patients were submitted to surgical procedure due to coronary artery and/or valvular disease at InCor-HCFMUSP. From this record, data of 2/3 of the patients were used for model development (bootstrap technique), and 1/3 for internal validation of the model. The performance of the model (InsCor) was compared to the 2000 Bernstein-Parsonnet (2000BP) and EuroSCORE (ES) complexes. Results: Only 10 variables were selected: age > 70 years, female sex; coronary revascularization + valve, myocardial infarction < 90 days; reoperation; surgical treatment of aortic valve; surgical treatment of tricuspid valve; creatinine < 2mg/dL; ejection fraction < 30%, and events. The Hosmer Lemeshow test for the InsCor was 0.184, indicating excellent calibration. The area under the ROC curve was 0.79 for the InsCor, 0.81 for the ES and 0.82 for 2000BP, confirming that the models are good and have similar discrimination. Conclusions: The InsCor and ES performed better than 2000BP at all stages of validation, but the new model, in addition to showing identification with the local risk factors, is simpler and more objective for mortality prediction in patients undergoing surgery due to coronary and/or valvular disease at InCor-HCFMUSP (Arq Bras Cardiol. 2013;100(3):246-254).
- Analysis of > 100,000 Cardiovascular Surgeries Performed at the Heart Institute and a New Era of Outcomes(2020) V, Omar A. Mejia; LISBOA, Luiz Augusto Ferreira; CANEO, Luiz Fernando; ARITA, Elisandra Trevisan; BRANDAO, Carlos Manuel de Almeida; DIAS, Ricardo Ribeiro; COSTA, Roberto; JATENE, Marcelo Biscegli; POMERANTZEFF, Pablo Maria Alberto; DALLAN, Luis Alberto Oliveira; JATENE, Fabio BiscegliBackground: The current challenge of cardiovascular surgery (CVS) is to improve the outcomes in increasingly severe patients. In this respect, continuous quality improvement (CQI) programs have had an impact on outcomes. Objective: To assess the evolution of the incidence and mortality due to CVS, as well as the current outcomes of the Hospital das Clinicas Heart Institute of the University of Sao Paulo Medical School (InCor-HCFMUSP). Methods: An outcome analysis of CVSs performed at the InCor, between January 1984 and June 2019. We observed the surgical volume and mortality rates in 5 time periods: 1st (1984-1989), 2nd (1990-1999), 3rd (2000-2007), 4th (2008-2015) and 5th (2016-2019). The CQI program was implemented between 2015 and 2016. The analysis included the total number of surgeries and the evolution of the most frequent procedures. Results: A total of 105,599 CCVs were performed, with an annual mean of 2,964 procedures and mortality of 5,63%. When comparing the 4th and the 5th periods, the average global volume of surgeries was increased from 2,943 to 3,139 (p = 0.368), bypass graft (CABG), from 638 to 597 (p = 0.214), heart valve surgery, from 372 to 465 (p = 0.201), and congenital heart disease surgery, from 530 to 615 (p = 0.125). The average global mortality went from 7.8% to 5% (p < 0.0001); in CABG surgery, from 5.8% to 3.1% (p < 0.0001); in heart valve surgery, from 14% to 7.5% (p < 0.0001) and in congenital heart disease surgery, from 12.1% to 9.6% (p < 0.0001). Conclusion: In spite of a recent trend towards increased surgical volume, there was a significant decrease in operative mortality in the groups studied. After the implementation of the CQI program, the mortality rates were closer to international standards.
- The Double-Orifice Technique in Mitral Valve Repair: 35 Years of History(2021) POMERANTZEFF, Pablo Maria Alberto; BRANDAO, Carlos Manuel de Almeida; RISO, Arlindo; JATENE, Fabio Biscegli
- Carcinoid Heart Disease: A Case Report and Literature Review(2023) COSTA, Isabela Bispo Santos da Silva; MELO, Edielle de Sant Anna; FURTADO, Armando; SOBRAL-ALVES, Juliana Barbosa; RIZK, Stephanie Itala; BENVENUTI, Luiz Alberto; ROCHITTE, Carlos E.; BRANDAO, Carlos Manuel de Almeida; POMARENTZEFF, Pablo Maria; BITTAR, Cristina Salvadori; GALAS, Filomena Regina Barbosa Gomes; AULER JUNIOR, Jose Otavio Costa; HOFF, Paulo Marcelo Gehm; KALIL FILHO, Roberto; JATENE, Fabio Biscegli; HAJJAR, Ludhmila Abrahao